Provexis logo

PXS - Provexis Share Price

0.69p 0.1  9.5%

Last Trade - 3:01pm

Sector
Consumer Defensives
Size
Micro Cap
Market Cap £13.0m
Enterprise Value £12.2m
Revenue £322k
Position in Universe 1474th / 1819
Bullish
Bearish
Unlock PXS Revenue
Momentum
Relative Strength (%)
1m -21.4%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -41.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.004 0.038 0.092 0.23 0.24 0.32 +140.9%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 March 2019, Provexis plc revenues increased 37% to £322K. Net loss increased 14% to £513K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development costs increase of 26% to £230K (expense), Share-based payment charges increase of 40% to £149K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

PXS Revenue Unlock PXS Revenue

Net Income

PXS Net Income Unlock PXS Revenue

Normalised EPS

PXS Normalised EPS Unlock PXS Revenue

PE Ratio Range

PXS PE Ratio Range Unlock PXS Revenue

Dividend Yield Range

PXS Dividend Yield Range Unlock PXS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
PXS EPS Forecasts Unlock PXS Revenue
Profile Summary

Provexis plc is engaged in developing and licensing the Fruitflow heart-health functional food ingredient for the global functional food sector. Fruitflow is a tomato extract, which inhibits platelet aggregation that causes heart attack, stroke and venous thrombosis. The syrup and powder versions of Fruitflow are used in foods, beverages and supplements. The powder version is used in a range of products, including soft gels, capsules, tablets and stick packs. The Company also offers Fruitflow + Omega-3 dietary supplement product, which is a two-in-one supplement in an easy to take capsule supporting healthy blood flow and normal heart function. Fruitflow + Omega-3 dietary supplement product is available through its e-commerce Website www.fruitflowplus.com. The Company's subsidiaries include Provexis Nutrition Limited, Provexis Natural Products Limited and Provexis (IBD) Limited, which are engaged in providing functional food, medical food and dietary supplement technologies.

Directors
Last Annual March 31st, 2019
Last Interim March 31st, 2019
Incorporated April 15, 2004
Public Since June 24, 2005
No. of Shareholders: n/a
No. of Employees: 4
Sector Consumer Defensives
Industry Food & Tobacco
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 2,059,321,507
Free Float (0.0%)
Eligible for
ISAs
SIPPs
PXS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for PXS
Upcoming Events for PXS
Frequently Asked Questions for Provexis
What is the Provexis share price?

As of 3:01pm, shares in Provexis are trading at 0.69p, giving the company a market capitalisation of £13.0m. This share price information is delayed by 15 minutes.

How has the Provexis share price performed this year?

Shares in Provexis are currently trading at 0.69p and the price has moved by 0.110k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Provexis price has moved by 0.148k% over the past year.

What are the analyst and broker recommendations for Provexis?

There are no analysts currently covering Provexis.

When will Provexis next release its financial results?

Provexis is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-03-31
What is the Provexis dividend yield?

Provexis does not currently pay a dividend.

Does Provexis pay a dividend?

Provexis does not currently pay a dividend.

When does Provexis next pay dividends?

Provexis does not currently pay a dividend.

How do I buy Provexis shares?

To buy shares in Provexis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Provexis?

Shares in Provexis are currently trading at 0.69p, giving the company a market capitalisation of £13.0m.

Where are Provexis shares listed? Where are Provexis shares listed?

Here are the trading details for Provexis:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: PXS
What kind of share is Provexis?

Based on an overall assessment of its quality, value and momentum, Provexis is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Provexis share price forecast 2020?

We were not able to load any forecast data for Provexis.

How can I tell whether the Provexis share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Provexis. Over the past six months, the relative strength of its shares against the market has been 19.52%. At the current price of 0.69p, shares in Provexis are trading at 3.18% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Provexis PE Ratio?

We were not able to find PE ratio data for Provexis.

Who are the key directors of Provexis?

Provexis's management team is headed by:

C. Dawson Buck - NEC
Niamh O'Kennedy - CSO
Ian Ford - SEC
Frederic Boned - NED
Who are the major shareholders of Provexis?

Here are the top five shareholders of Provexis based on the size of their shareholding:

Lucas (Stuart) Individual Investor
Percentage owned: 9.02% (185.8m shares)
DSM Venturing B.V. Venture Capital
Percentage owned: 6.98% (143.8m shares)
Lucas (Kiman) Individual Investor
Percentage owned: 1.52% (31.3m shares)
Milligan (James) Individual Investor
Percentage owned: 1.27% (26.3m shares)
Buck (Charles Dawson) Individual Investor
Percentage owned: 1.23% (25.4m shares)
Similar to PXS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.